Tetra Pharm Technologies avanza el antagonista de CB1, TPT0701, para la supresión del apetito

Posted on by

-Tetra Pharm Technologies avanza el antagonista de CB1, TPT0701, para la supresión del apetito en pruebas preclínicas La empresa biofarmacéutica danesa Tetra Pharm Technologies se enorgullece de anunciar un hito importante en el ámbito de la investigación sobre la supresión del apetito al…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.